WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed

An essential line of defence in a global living-with-COVID-19 policy is formed by
effective therapeutic strategies for vulnerable patients,1 many of whom are excluded
from treatment with nirmatrelvir–ritonavir (sold as Paxlovid, Pfizer) by virtue of
their comorbidities or interacting medications. Preliminary data suggest that monoclonal
antibodies (mAbs) is highly effective for these groups,2 and WHO, in its Therapeutics
and COVID-19: Living Guideline,3 has previously conditionally recommended the use
of sotrovimab (sold as Xevudy, Vir Biotechnology and GlaxoSmithKline) or casirivimab–imdevimab
(sold as Ronapreve, Regeneron) for people at high risk of hospitalisation.

Related Keywords

United Kingdom ,London ,City Of , ,Glaxosmithkline ,University College London ,United Kingdom National Health Service ,Amgen ,United Kingdom National Virology Consortium ,Genentech ,Elsevier Ltd ,University College London Hospitals ,International Units ,Pfizer ,Kings Cross Health Research Authority ,Astrazeneca ,International Standard ,Sarah Canon Research Institute ,Francis Crick Institute ,London Camden ,University College ,Bicycle Therapeutics ,Apogen Biotech ,Epic Biosciences ,Achilles Therapeutics ,Principal Investigator ,